LUM-201 phase 2 data for PGHD with Andrew Dauber, MD, MMSc
Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to discuss potential advantages of LUM-201 as it goes through the clinical pipeline.
In this Contemporary Pediatrics interview, Andrew Dauber, MD, MSSc, Chief of Endocrinology at Children’s National Hospital in Washington, DC, broke down and highlighted phase 2 data for LUM-201 (Lumos Pharma), an oral secretagogue in development for moderate pediatric growth hormone deficiency (PGHD).1,2
Data was initially presented via 2 posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, Massachusetts, from June 2-4, 2024. According to the poster titled, "Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD) Key Discoveries from Phase 2 of OraGrowtH212 Trial," the phase 2 study objective was to evaluate LUM-201 in children with PGHD. Results demonstrated that at 6 months on LUM-201, a significant increase over baseline in key parameters was observed for the 1.6 mg/kg/day dose, according to a press release from Lumos. At baseline GH, secretion was 0.19 ±0.09 μg/kg/12-hrs; pulsatile GH was 1.17 ±0.66 μg/kg/12-hrs; and total GH was 1.35 ±0.66 μg/kg/12-hrs.1,2
"It was determined that at [6] months GH secretion was 3.3 ±1.8 to 4.4 ±2.1 μg/kg/day compared to 5.0 ±1.3 μg/kg/day derived from published data in normal children, indicating restoration of approximately normal GH secretion by LUM-201," stated Lumos.1
"It's a medicine that stimulates the pituitary gland and the hypothalamus, telling your body to produce more growth hormone," Dauber said in the above video. "It binds to a receptor in both those regions, something called the growth hormone secretagogue receptor, and when it binds, it tells the pituitary, ultimately, to secrete more growth hormone."
Dauber previously spoke with Contemporary Pediatrics discussing the role of the pediatrician and treating PGHD.
References:
1. Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024. Lumos Pharma. Press release. June 4, 2024. Accessed September 9, 2024. https://investors.lumos-pharma.com/news-releases/news-release-details/lumos-pharma-announces-new-analyses-phase-2-oragrowth212-trial
2. Cassorla F, Roman R, Johnson ML, et al. Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD) Key Discoveries from Phase 2 of OraGrowtH212 Tria. Poster presentation presented at: 2024 Annual Meeting of the Endocrine Society (ENDO). Boston, Massachusetts. June 2-4, 2024.
